Expression and Prognostic Significance of Wnt7a in Human Endometrial Carcinoma

Table 5

Multivariate survival analysis of PFS and OS in 70 patients with endometrial carcinoma.

	HR	95% CI	𝑃^∗-value
Progression-free survival
FIGO stage	5.571	0.983–31.567	0.052
Grade	2.493	0.213–29.171	0.467
Lymph node metastasis	0.700	0.190–2.578	0.592
Depth of myometrial invasion	1.766	0.286–10.902	0.540
LVS involvement	3.983	0.463–34.249	0.208
Peritoneal cytology	8.497	1.664–43.376	0.010
Wnt7a expression	0.193	0.019–1.955	0.164
Overall survival
FIGO stage	1.734	0.469–6.407	0.409
Grade	0.839	0.080–8.844	0.884
Lymph node metastasis	0.846	0.238–3.006	0.797
LVS involvement	7.683	0.867–68.043	0.067
Peritoneal cytology	5.082	1.258–20.525	0.022
Wnt7a expression	0.737	0.116–4.696	0.747

FIGO: International Federation of Gynecology and Obstertics; LVS: lymph vascular space; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval and *Cox regression test.